Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy

J. Paul Monk, Susan Halabi, Joel Picus, Arif Hussain, George Philips, Ellen Kaplan, Tim Ahles, Lin Gu, Nicholas Vogelzang, William K. Kelly, Eric J. Small

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background: The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial. Peripheral androgen blockade using a combination of a 5-alpha reductase inhibitor and an antiandrogen may allow control of the prostate-specific antigen (PSA). Because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression. Methods: All patients had undergone previous definitive local therapy and had evidence of a rising PSA >1ng/mL, with no evidence of recurrent disease. Patients received both finasteride, 5 mg orally per day, and flutamide, 250 mg orally 3Ã - a day. Patients were followed for a PSA response and quality of life assessment. Results: Ninety-nine of 101 accrued patients were eligible. A a≤yen;80% PSA decline was seen in 96 (96%) patients. The median time to PSA progression was 85 months. With a median follow-up of 10 years, the median survival time had not been reached, and the 5-year overall survival rate was 87%. Toxicity was mild, with 18 patients stopping for toxicity; 15 had diarrhea, 4 had gynecomastia, and 3 had transaminase elevation. Baseline Functional Assessment of Cancer Therapy Prostate Module and Treatment Outcome Index scores decreased by 5 points each at 6 months after enrollment. Conclusions: The use of the finasteride/flutamide combination is feasible, and results in PSA declines of a≤yen;80% in 96% of patients with serologic progression after definitive local therapy. There were no unexpected toxicities, and the change in quality of life was mild. Further evaluation of this or a similar regimen in a controlled clinical trial is warranted.

Original languageEnglish
Pages (from-to)4139-4147
Number of pages9
JournalCancer
Volume118
Issue number17
DOIs
StatePublished - Sep 1 2012

Keywords

  • PSA failure
  • finasteride
  • flutamide
  • prostate cancer
  • quality of life

Fingerprint Dive into the research topics of 'Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy'. Together they form a unique fingerprint.

  • Cite this

    Monk, J. P., Halabi, S., Picus, J., Hussain, A., Philips, G., Kaplan, E., Ahles, T., Gu, L., Vogelzang, N., Kelly, W. K., & Small, E. J. (2012). Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy. Cancer, 118(17), 4139-4147. https://doi.org/10.1002/cncr.26732